New Risk • Dec 03
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (12% average weekly change). Shareholders have been substantially diluted in the past year (346% increase in shares outstanding). 공시 • Jul 15
More Impact AG, Annual General Meeting, Aug 21, 2025 More Impact AG, Annual General Meeting, Aug 21, 2025, at 11:00 W. Europe Standard Time. 공시 • Jul 02
More Impact AG Announces Supervisory Board Changes More Impact AG announced that the Frankfurt District Court has appointed Prof. Dr. Stefan Hegemann as a new member of the Supervisory Board following a proposal by the company. He succeeds Dr. Karsten Behlke, who has resigned from office to move to the operational business of More Impact AG. Prof. Hegemann will stand for election to the Supervisory Board at the company's upcoming Ordinary General Meeting on August 21, 2025. With his long-standing experience as a medical doctor and his comprehensive scientific know-how, Prof. Hegemann will support More Impact in its future growth. He is a honorary professor of the University of Zurich and is also the founder of the renowned "Balance Clinic". Prof. Hegemann was head physician at the Department of Otorhinolaryngology and Facial Surgery of the University Hospital Zurich for several years. He also worked at the Johns Hopkins University in Baltimore and the Karlsbad-Langensteinbach Clinic. He completed his medical studies at the University of Essen, the LMU Munich, the McMaster University Hamilton and the University of Cape Town in South Africa. Prof. Hegemann is a member of the Prosper Menière Society, the Association of German-speaking Audiologists and Neurootologists (ADANO) and the Robert Barány Society. He is also a member of both the German Society for ENT and Neurology, Head and Neck Surgery and the Swiss Society for Otorhinolaryngology, Neck and Facial Surgery. In addition, he has been honoured with several accolades, including the ADANO Innovation Award. New Risk • Apr 29
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €85.8m (US$97.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (14% average weekly change). Shareholders have been substantially diluted in the past year (over 8x increase in shares outstanding). Minor Risk Market cap is less than US$100m (€85.8m market cap, or US$97.9m). 공시 • Apr 10
More Impact AG and BG Braingate Technology GmbH Introduces Z-Boxx as an Innovative Smoking Cessation Product More Impact AG and its wholly owned subsidiary BG Braingate Technology GmbH are launching the Z-Boxx. Braingate is thus integrating its patented inhaler technology into a marketable product. The Z-Boxx allows smokers to gradually quit nicotine without having to give up the smoking experience. The Z-Boxx thus makes an active contribution to improving health and also significantly reduces the burden on the environment by avoiding waste. The comprehensive market launch of the innovative product is planned for the fourth quarter of 2025. The Z-Boxx is based on an innovative, patented filter and vaporization technology that heats tobacco instead of burning it. The actual nicotine dosage can be regulated so that the Z-Boxx can be used to continuously reduce the smoker’s nicotine intake – right up to complete nicotine abstinence. In addition, no typical combustion products such as tar or carbon monoxide are produced. The mechanism of action of the Z-Boxx therefore directly addresses the most harmful aspects of smoking. Nevertheless, the smoking experience remains authentic in taste. Compared to disposable e-cigarettes or traditional tobacco products, the Z-Boxx produces no environmentally harmful filter waste, as filterless cigarettes are used and harmful substances are filtered out. According to the WHO, an estimated 4.5 trillion cigarette filters end up in the environment worldwide every year. The battery of the Z-Boxx can also be flexibly removed and recharged, which significantly reduces electronic waste. New Risk • Mar 01
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €95.2m (US$98.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (25% average weekly change). Shareholders have been substantially diluted in the past year (over 8x increase in shares outstanding). Minor Risk Market cap is less than US$100m (€95.2m market cap, or US$98.7m). 